This message was originally sent on 10/23/21. It is being re-issued with a correction and updates.

This message is intended for all healthcare providers in Los Angeles County. Please distribute as appropriate.

Correction and New Resources

Correction
The COVID-19 Vaccine Update that was issued on October 23 contained an error in the Moderna COVID-19 vaccine booster dose. The correct dose is 50 μg in 0.25 ml (not 0.25 mg). This has been corrected in the original LAHAN below and online.

LAC DPH Booster Resources
- The LAC DPH COVID-19 Vaccine Eligibility Summary tables for providers and patients have been updated to include that immunocompromised individuals who have received a 3rd dose of mRNA vaccine may receive a booster dose at least 6 months after their 3rd dose.
- Two new patient infographics are now available: Booster Doses and Doses for People Who Are Immunocompromised. There is also a two-page combined infographic.

Please see the original corrected LAHAN below.
Expanded Eligibility for COVID-19 Vaccine Booster Shots

After authorization by the Food and Drug Administration, the Centers for Disease Control and Prevention have expanded the recommendations for booster shots to include Moderna and Johnson and Johnson/Janssen (J&J) COVID-19 vaccines as well as heterologous (mix and match) dosing.

Key new CDC booster recommendations:

- **All persons who received a J&J COVID-19 vaccine** should get a single vaccine booster dose **at least 2 months** after their initial J&J dose. The booster can be J&J or either of the mRNA vaccines.
- **Certain people who received Moderna** for their primary series should receive a single vaccine booster dose **at least 6 months** after completing the series. The group of eligible persons is the same as for Pfizer and listed below. Note that the Moderna COVID-19 vaccine booster dose is a half dose (50 μg in 0.25 ml).
- Individuals may choose which of the 3 authorized vaccines they would like to receive if they are eligible for a booster dose.

Booster eligibility for individuals who received either Pfizer or Moderna primary COVID-19 vaccine series

- A booster is **recommended** for:
  - People 65 years and older
  - Residents of long-term care facilities
  - People age 50–64 years with an **underlying medical condition** or are at **risk of social inequities**
- A booster **may be considered** for:
  - People age 18-49 years with an **underlying medical condition**
  - People age 18-64 years who are at higher risk of COVID-19 exposure due to their occupational or institutional setting; this includes all essential workers.

These recommendations have been endorsed by the Western States Scientific Safety Review Workgroup.

**Upcoming CDC Booster Dose Resources**

- The CDC is in the process of updating their COVID-19 vaccine **clinical considerations** and will be releasing an MMWR on the ACIP recommendations.
- The CDC is also hosting a live webinar for healthcare providers: **What Clinicians Need to Know About the Recent Updates to CDC’s Recommendations for COVID-19 Booster Vaccination** Tuesday October 26, 11am-12 pm PST. [Webinar details](#).

**LAC DPH Booster Resources**

- **For providers:** COVID-19 Vaccine Eligibility Summary Table. This table summarizes vaccine eligibility based on the primary series received and the patient age and/or risk factors.
- **For patients:** Booster Dose How to Get Vaccinated webpages (English and Spanish); a COVID-19 Vaccine Eligibility Summary Table in English and Spanish; updated patient vaccine FAQs in English. The [www.VaccinateLACounty.com](http://www.VaccinateLACounty.com) website hosts all COVID-19 vaccine related resource for the public.

See the COVID-19 Vaccine Eligibility Summary Table for Healthcare Providers on the last page.
Visit the LAC DPH COVID-19 Provider Hub and Vaccination Hub
Refresh your browser to view the latest version.

This communication was sent by Claire Jarashow, Director, Vaccine Preventable Disease Control Program, Los Angeles County Department of Public Health
This table summarizes COVID-19 vaccine eligibility based on the primary series received and the patient age and/or risk factors. The most current version of this table is available online.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Dose</th>
<th>Age</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>12-17</td>
</tr>
<tr>
<td>Pfizer/Comirnaty &amp; Moderna</td>
<td>Primary 2-dose series</td>
<td>Pfizer only</td>
</tr>
<tr>
<td></td>
<td>Third dose (&quot;additional dose&quot;)&lt;sup&gt;2&lt;/sup&gt; recommended for moderate to severely immunocompromised persons &lt;br&gt; at least 28 days after 2&lt;sup&gt;nd&lt;/sup&gt; dose</td>
<td>Pfizer only</td>
</tr>
<tr>
<td></td>
<td>Booster dose&lt;sup&gt;3&lt;/sup&gt; recommended at least 6 months after primary series&lt;sup&gt;4&lt;/sup&gt; if the individual:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Resides in a long-term care facility</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>- Has underlying medical condition or increase risk of social inequities</td>
<td>May receive</td>
</tr>
<tr>
<td></td>
<td>- Has increased risk of exposure from work or institutional setting</td>
<td>May receive</td>
</tr>
<tr>
<td></td>
<td>- Is moderately to severely immunocompromised&lt;sup&gt;4&lt;/sup&gt;</td>
<td>May receive</td>
</tr>
<tr>
<td>Janssen/Johnson &amp; Johnson (J&amp;J)</td>
<td>Primary single-dose series</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Booster dose recommended&lt;sup&gt;3,5&lt;/sup&gt; at least 2 months after the 1&lt;sup&gt;st&lt;/sup&gt; dose</td>
<td>✓</td>
</tr>
</tbody>
</table>

1. Moderna has two dose volumes. The full dose (100 μg in 0.5 ml) is authorized for both the primary series and the 3rd dose for persons who are immunocompromised (IC). A half dose (50 μg in 0.25 ml) is authorized for booster doses.
2. The third dose of mRNA vaccine should be the same vaccine product as the primary series, whenever possible.
3. Booster doses can be the same vaccine as was given in the primary series or it can be a mix-and-match dose. Note: a Moderna booster dose is a half dose (50 μg in 0.25 ml).
4. Those who have had a 3<sup>rd</sup> dose of mRNA vaccine due to IC may receive a booster dose ≥ 6 months after their 3<sup>rd</sup> dose. If a Moderna vaccine is used, it should be the booster dose and volume (50 μg in 0.25 ml).
5. All persons who received J&J as their primary dose should get a booster dose (including those who are IC at least 2 months (8 weeks) later. IC persons who received one primary dose of J&J should not receive more than two COVID-19 vaccines in total- if Moderna is used, it should be the half-dose.

For more information, see CDC Clinical Considerations for Use of COVID-19 Vaccines